Iloperidone is indicated for the following conditions-

• Schizophrenia

Schizophrenia

• The recommended target dosage of Iloperidone tablets is 12 to 24 mg/day administered twice daily.
• This target dosage range is achieved by daily dosage adjustments, alerting patients to symptoms of orthostatic hypotension, starting at a dose of 1 mg twice daily, then moving to 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg twice daily on Days 2, 3, 4, 5, 6, and 7 respectively, to reach the 12 mg/day to 24 mg/day dose range. Iloperidone can be administered without regard to meals.

Side effects reported with the use of Iloperidone include-

• dizziness
• dry mouth
• fatigue
• nasal congestion
• orthostatic hypotension
• somnolence
• tachycardia
• weight gain

Dizziness	Dry Mouth	Fatigue
Congestion	Somnolence	Tachycardia

• Elderly patients with dementia-related psychosis who are treated with atypical antipsychotic drugs are at an increased risk of death and cerebrovascular-related adverse events, including stroke.
• QT prolongation: Prolongs QT interval and may be associated with arrhythmia and sudden death—consider using other antipsychotics first.
• Avoid use of Iloperidone in combination with other drugs that are known to prolong QTc; use caution and consider dose modification when prescribing Iloperidone with other drugs that inhibit Iloperidone metabolism. Monitor serum potassium and magnesium in patients at risk for electrolyte disturbances.
• Neuroleptic Malignant Syndrome: Manage with immediate discontinuation of drug and close monitoring.
• Tardive dyskinesia: Discontinue if clinically appropriate